Adma Biologics, INC

ADMA Biologics reported Q1 2026 financial results with flat total revenue of $114.5 million, but saw a 22% increase in Adjusted Net Income to $40.7 million and a 24% rise in Adjusted EBITDA to $59.7 million, driven by strong ASCENIV performance and improved gross margins.

ADMA Biologics announces FDA approval to expand the label for its ASCENIV product to include pediatric immune compromised patients aged two years and older.

ADMA Biologics refutes allegations by Culper Research, asserting strong demand for its immune globulin products and standard inventory practices.

ADMA Biologics initiates a $125 million accelerated share repurchase as part of its $500 million program, signaling strong financial health and confidence in its stock.

ADMA Biologics announced record full-year 2025 financial results, driven by strong ASCENIV demand, and provided robust financial guidance through 2029, alongside a CFO transition.

ADMA Biologics announced preliminary unaudited full year 2025 revenue of $510-$511 million, exceeding prior guidance, and raised its financial outlook for 2026 and 2027.

ADMA Biologics reports strong Q1 2026 net income of $45.3 million, driven by ASCENIV growth and improved manufacturing yields.

ADMA Biologics reported a 12% revenue increase in Q3 2025, driven by ASCENIV sales, alongside a significant debt refinancing and share repurchase program.

ADMA Biologics reported significant revenue and gross profit increases for Q2 2025, driven by strong ASCENIV sales and operational efficiencies, while also refinancing its senior credit facility.

ADMA Biologics reports a 40% increase in revenue for Q1 2025, driven by strong sales of ASCENIV, and announces FDA approval of its yield enhancement production process.

ADMA Biologics reports a significant increase in revenue and net income for the third quarter of 2024, driven by strong sales of its immunoglobulin products and improved manufacturing efficiencies.

ADMA Biologics reports a significant increase in revenue and a return to profitability in the second quarter of 2024, driven by strong sales of its immunoglobulin products.

ADMA Biologics achieved significant revenue and gross profit growth in 2025, driven by strong ASCENIV sales and manufacturing efficiencies, despite a reported net income decrease influenced by a prior-year tax benefit.

ADMA Biologics achieves first-ever GAAP net income, reporting $197.7 million for 2024 and projecting significant revenue and earnings growth for 2025 and 2026.

ADMA Biologics announces its FY2023 financial results, marking its transition to a Large Accelerated Filer and highlighting revenue growth and strategic initiatives.

Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance of Adma Biologics, Inc., reported a transaction in 3,177 shares of common stock on July 24, 2026.

Terry Kohler, CFO and Treasurer of Adma Biologics, Inc., reported multiple transactions in common stock on July 16, 2026.

ADMA Biologics Director Jerrold B. Grossman acquired 6,400 shares of common stock in an open market transaction.

Jerrold Grossman, a Director at ADMA Biologics, Inc., reported the acquisition of 12,500 shares of common stock on May 12, 2026.

Director Jerrold B. Grossman acquired 12,500 shares of ADMA Biologics common stock in an open market transaction.

Kaitlin M. Kestenberg-Messina, COO and SVP of Compliance at ADMA Biologics, reported a transaction involving 20,362 shares of common stock on April 1, 2026, primarily for tax withholding purposes.

ADMA Biologics has scheduled its 2026 Annual Meeting of Stockholders for June 2, 2026, to address director elections, auditor ratification, and executive compensation.

ADMA Biologics, Inc. has filed a definitive proxy statement with the SEC.

ADMA Biologics has scheduled its 2025 annual meeting of stockholders for June 4, 2025, and released details regarding director nominations, executive compensation, and corporate governance.

ADMA Biologics has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.

ADMA Biologics will hold its annual stockholders meeting virtually on June 4, 2024, to vote on director elections and auditor ratification.

Vanguard Capital Management has reported beneficial ownership of 12,110,153 shares, representing 5.08% of the outstanding common stock of ADMA Biologics Inc.

The Vanguard Group reports 0% beneficial ownership in ADMA Biologics Inc. following an internal realignment.

Invesco Ltd. has reported a 5.0% beneficial ownership stake in ADMA Biologics Inc., holding 11,785,202 shares of common stock.

State Street Corporation has reported a 5.1% beneficial ownership stake in ADMA Biologics Inc., signaling significant institutional interest.

The Vanguard Group has reported a significant beneficial ownership stake of 8.94% in ADMA Biologics Inc., totaling over 21 million shares.

State Street Corporation has filed a Schedule 13G, reporting a 4.8% passive beneficial ownership stake in ADMA Biologics Inc. as of March 31, 2025.